Over two decades ago, Dr. Harry Shirkey coined the term """"""""therapeutic orphan"""""""" to emphasize the dearth of scientific knowledge in pediatric therapeutics. Despite advancements which have dramatically increased the knowledge base in Pediatric Clinical Pharmacology, a survey of the 1991 PDR found that 62% of all FDA-approved drugs listed did not contain pediatric dosage recommendations or alternatively, were not recommended for use in children. This demonstrates that our """"""""new knowledge"""""""" has done little to improve the approval process for drugs in infants and children. Nevertheless, we continue to expand the use of drugs in pediatric patients without the necessary and rigorous approach demanded by society for the development of drugs in adults. This dilemma is perpetuated b y: 1) an absence of a """"""""consortium"""""""" for pediatric pharmacology capable of working with the FDA and pharmaceutical manufacturers for pediatric drug development, 2) a regulatory mandate regarding the importance of pediatric drug research and 3) a societal """"""""misperception"""""""" that investigation in Pediatric Clinical Pharmacology is too difficult, too costly (i.e., insufficient return on investment) or places children at an unacceptable level of risk. Clearly, these problems are not insurmountable and must be rectified if we are to remove the stigma of the """"""""therapeutic orphan"""""""". A demonstrable step solving many of these problems resides with the establishment of the Pediatric Pharmacology Research Unit (PPRU) Network. Since 1988, the Section on Pediatric Clinical Pharmacology at the Arkansas Children's Hospital (ACH) has actively and aggressively pursued the main goal of the PPRU Network; namely, """"""""to increase the number and variety of medications that are FDA-approved for use in children, with the ultimate goal that all drugs prescribed for children be labeled for such use"""""""". This has been accomplished by the assembly of a state-of-the-art core laboratory facility, a Pediatric Clinical Research Unit and a group of professionals (3 MDs, 1 PhD, 2 PharmDs, 1 RN and 2 Research Associates) with formal training and/or experience in Clinical Pharmacology who have emphasized the investigation of both old and new drugs in neonates, infants, children and adolescents. The Section on Pediatric Clinical Pharmacology at ACH currently possesses the personnel, experience, facility and organizational requirements mandated for the establishment of a PPRU. Accordingly, this Unit is ideally suited to fully address the specific aims of the program: 1) to enable a locus for the pre- and post-marketing clinical evaluation of drugs for children in cooperation with industry, 2) to propose independent investigator initiated studies (i.e., clinical pharmacology of antihypertensive and diuretic agents in children, prospective identification and evaluation of drug toxicity/adverse drug effects), 3) to effectively participate in a network with other established Pediatric Clinical Pharmacology programs and 4) to provide an environment for collaborative training in Pediatric Clinical Pharmacology to increase the number of qualified investigators in this area. This will be accomplished by the organization of a PPRU at ACH which will be facilitated and sustained by this grant award. The research completed by this Unit and the PPRU Network over the next five years will form the framework necessary to elevate pediatric patients in the drug development process to a first priority status.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01HD031324-05
Application #
2634944
Study Section
Special Emphasis Panel (SRC (06))
Project Start
1994-03-21
Project End
1998-12-31
Budget Start
1998-01-01
Budget End
1998-12-31
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Arkansas Children's Hospital Research Institute
Department
Type
DUNS #
City
Little Rock
State
AR
Country
United States
Zip Code
72202
James, L; Ito, S (2009) Neonatal pharmacology: rational therapeutics for the most vulnerable. Clin Pharmacol Ther 86:573-7
James, L P; Wilson, J T; Simar, R et al. (2001) Evaluation of occult acetaminophen hepatotoxicity in hospitalized children receiving acetaminophen. Pediatric Pharmacology Research Unit Network. Clin Pediatr (Phila) 40:243-8
Gaedigk, A; Casley, W L; Tyndale, R F et al. (2001) Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 79:841-7
Gaedigk, A (2000) Interethnic differences of drug-metabolizing enzymes. Int J Clin Pharmacol Ther 38:61-8
James, L P; Stowe, C D; Farrar, H C et al. (1999) The pharmacokinetics of oral ranitidine in children and adolescents with cystic fibrosis. J Clin Pharmacol 39:1242-7
Wells, T G (1999) Trials of antihypertensive therapies in children. Blood Press Monit 4:189-92
Gaedigk, A; Gotschall, R R; Forbes, N S et al. (1999) Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 9:669-82
Marshall, J D; Kearns, G L (1999) Developmental pharmacodynamics of cyclosporine. Clin Pharmacol Ther 66:66-75
Marshall, J D; Abdel-Rahman, S; Johnson, K et al. (1999) Rifapentine pharmacokinetics in adolescents. Pediatr Infect Dis J 18:882-8
Marshall, J D; Wells, T G; Letzig, L et al. (1998) Pharmacokinetics and pharmacodynamics of bumetanide in critically ill pediatric patients. J Clin Pharmacol 38:994-1002

Showing the most recent 10 out of 16 publications